Comparative Pharmacology
Head-to-head clinical analysis: DOLISHALE versus VICODIN HP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLISHALE versus VICODIN HP.
DOLISHALE vs VICODIN HP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DOLISHALE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin neurotransmission.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways; acetaminophen inhibits cyclooxygenase and has antipyretic effects.
Adults: 200 mg orally twice daily or 400 mg orally once daily. Administer with food.
One tablet (hydrocodone bitartrate 10 mg/acetaminophen 660 mg) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10-14) in adults; prolonged in renal impairment (up to 24 hours with CrCl <30 mL/min)
Hydrocodone: 3.8-5.5 hours (mean 4.5 h). Acetaminophen: 2-3 hours. Clinical context: dosing interval every 4-6 hours for acute pain.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Primarily renal: hydrocodone is eliminated as conjugated metabolites (glucuronides) ~80%; unchanged drug ~5%. Biliary/fecal: minor, <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic